| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Medical Research Institute of New Zealand, 2 P3 Research, and 3 Wellington School of Medicine & Health Sciences, Wellington, New Zealand. 4 University of Southampton, Southampton, UK
CORRESPONDENCE: R. Beasley, Medical Research Institute of New Zealand, PO Box 10055, Wellington, New Zealand. Fax: 64 44729224. E-mail: richard.beasley@mrinz.ac.nz
Keywords: Adults, asthma, budesonide, dose-response, inhaled corticosteroids, meta-analysis
Received: July 3, 2003
Accepted December 15, 2003
 |
Abstract |
|---|
 TOP Abstract MethodsResultsDiscussionAcknowledgementsReferences |
|---|
A meta-analysis was carried out on placebo-controlled, randomised clinical trials, presenting data on at least one outcome measure of asthma and using at least two doses of budesonide, delivered by turbuhaler or metered-dose inhaler+spacer twice daily.
A total of six studies of 1,435 adolescents and adults, with mild to moderately severe asthma, met the inclusion criteria for the meta-analysis. A negative exponential model indicated that 80% of the benefit at 1,600 µg·day–1 was achieved at doses of 
200–400 µg·day–1 and 90% by 300–600 µg·day–1. Meta-regression with a quadratic term in dose showed that the maximum effect was obtained with doses of 1,000 µg·day–1.
In conclusion, the available published data indicate that, in adolescents and adults with mild to moderate asthma, most of the therapeutic benefit of budesonide delivered by turbuhaler or metered-dose inhaler+spacer is achieved with a dose of 400 µg·day–1 and the maximum effect is achieved at 1,000 µg·day–1. This conclusion is qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids and that the subjects included in this meta-analysis had predominantly mild to moderate asthma.
In a recent meta-analysis of the dose-response relationship of fluticasone, it was shown that most of the therapeutic benefit is achieved with doses of 100–250 µg·day–1, and that the maximum effect is obtained at
500 µg·day–1 in adolescents and adults with asthma 1. This therapeutic dose range is two-fold lower than that recommended in the international and national consensus guidelines and formularies, and the dose commonly prescribed in clinical practice 2–4. In view of this disparity and in response to the recommendations of the Cochrane Centre 5, the current authors have further investigated the therapeutic dose range of inhaled corticosteroids by undertaking a similar meta-analysis of the dose-response relationship of budesonide. |
Methods |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
Inclusion criteria
Two people examined each paper's title and abstract, and then the full paper if necessary. To be included in the primary meta-analysis, studies had to meet all of the following criteria: a double-blind, placebo-controlled, randomised trial involving two or more doses of budesonide, delivered by turbuhaler or metered-dose inhaler (MDI)+spacer device twice daily, in adolescents (aged >12 yrs) or adults with asthma, of at least 4 weeks in duration. The decision to include studies using the turbuhaler and MDI+spacer was based on evidence that both delivery systems achieved similar lung deposition, greater than that with the MDI alone 6, 7, although it is noted that a formal dose-response comparison between the two devices was not undertaken. The search strategy recommended by the QUORUM statement is shown in figure 1
. Letters were sent to the authors of three out of six studies included in the meta-analysis to obtain the data in the format required.
|
Data analysis
For each outcome measure, the mean change reported in each study was plotted against the total daily dose of budesonide. A negative exponential curve of the mean relative percentage change from baseline for each outcome measure was modelled, weighted by the number of participants in the study. From this graph, the doses at which 80 and 90% of the effect obtained with 1,600 µg·day–1 were determined. The effect obtained with 1,600 µg·day–1 was considered to be the "maximum effect" for the purposes of this analysis. The confidence intervals of the outcome measures of this model could not be estimated from the published data.
Meta-regression was used to compare the effect of change in dose of budesonide on the asthma response variables. A general linear model, weighted by the inverse of the calculated variance for each variable, was used 8, 9. Scatter plots of the response and explanatory variable (the total daily dose of inhaled budesonide) suggested a curved relationship, therefore, a quadratic model was used for this measure. The variance for each response variable was calculated from the sd or se cited in the extra data from the authors, by using the initial number of patients for each treatment category. Analysis of residuals indicated that normality and other assumptions were met. The peak dose effect for the quadratic model was calculated by the following equation:
|
| (001) |
A meta-analysis was undertaken to establish the difference in effect on FEV1 and PEF of an inhaled dose of 400 µg·day–1 budesonide, as compared with higher doses, based on the standardised difference in FEV1 and PEF for the studies in which these data were available 10. The standardised difference represented the differences in the means, divided by the pooled within-groups sd. Both fixed- and random-effects models were fitted.
Due to heterogeneity between studies and the low numbers involved, it was not possible to perform a meaningful statistical analysis of the data for withdrawals due to exacerbations of asthma. Likewise, the relatively high frequency of withdrawals due to events other than an exacerbation of asthma in two of the four studies that reported these data also meant that the total withdrawal data could not be analysed.
|
Results |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
). A total of 1,435 adolescents and adults with asthma were included in the studies, with a mean age (range) of 41 yrs (12–70). In most studies, the patients had mild to moderately severe asthma, with a mean FEV1 of 69% pred at enrolment. The doses of budesonide ranged 200–1,600 µg·day–1; only one study used a dose of budesonide >800 µg·day–1. The funnel plots (data not shown) did not suggest publication bias, although it is acknowledged that with only six studies, this provides only limited support.
|
Determination of the dose at which 80 and 90% of the effect obtained with 1,600 µg·day–1 is achieved
From the negative exponential line of best-fit derived from the weighted means of the effect at each dose, it was calculated that 80% of the benefit obtained with 1,600 µg·day–1 was achieved at doses of 200–400 µg·day–1 and 90% at doses of 300–600 µg·day–1, depending on the outcome measure (table 2). The plot of the per cent predicted maximum effect based on the negative exponential model for all four major clinical outcome measures is shown in figure 2.
|
|
). The maximum increase in FEV1 was 0.32 L, utilising the fixed-effects model.
|
800 µg·day–1 (fig. 3).
|
800 µg·day–1 (fig. 4).
|
). Examination of the individual study data indicate that most of the benefit with respect to the reduction in asthma exacerbations leading to withdrawal was achieved with a dose of 400 µg·day–1.
|
|
Discussion |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
400 µg and that the maximum achievable benefit occurs with a dose of 1,000 µg. Given that in vitro and clinical studies have indicated a 2:1 potency ratio of fluticasone to budesonide and beclomethasone dipropionate (BDP) 17–19, these findings are strongly consistent with the previous fluticasone meta-analysis, which showed that 90% of clinical benefit was achieved with doses in the range of 150–250 µg·day–1 and the peak effect with a dose of 500 µg·day–1 1. These findings are also consistent with the recent large dose-response study of BDP administered via MDI, which reported that the top of the dose-response curve in terms of efficacy was between 400–800 µg·day–1, depending on the outcome measure examined 20. Together, these findings allow determination of the therapeutic dose-response relationship of the different inhaled corticosteroids used in clinical practice, depending on their relative potencies.
Limitations of the study
The major limitation of this meta-analysis was the paucity of studies using high doses of budesonide; only one study examined a dose >800 µg·day–1. Consequently, one of the findings is that data in the published literature on which to confidently determine the dose relationship of budesonide at high doses is limited. The authors are confident that all available studies were included in the analysis because of the comprehensive search that was undertaken.
The authors were concerned that the requirement for the studies to be placebo-controlled may have led to the exclusion of a number of large dose-response studies examining doses of budesonide >800 µg·day–1 and that their inclusion would have enabled the dose-response to be determined at the higher level. However, this was not the case, as only two nonplacebo-controlled studies identified examined doses of >800 µg·day–1 21, 22 and these studies indicated that there was a minimal additional benefit of using doses up to 3,200 µg·day–1.
For reasons stated previously, the authors were unable to undertake a meaningful statistical analysis of withdrawals due to worsening asthma. However, examination of data from individual studies suggested that most of the benefit is achieved with a dose of 400 µg·day–1. For example, in the large study of Busse et al. 11, budesonide at a dose of 400 µg·day–1 led to a reduction in withdrawals from asthma from 57 to 10%, with the 1,600 µg·day–1 dose causing a minimal further reduction to 7%.
It is also acknowledged that the greater number of withdrawals on placebo may have led to an underestimation of the magnitude of the difference in lung function and symptoms between placebo and budesonide. This consideration did not apply to the comparisons between the 400, 800 and 1,600 µg doses of budesonide, in which the proportion of withdrawals was similar.
Another issue is the intersubject variation in response to inhaled corticosteroid therapy, which is likely to result in a proportion of patients requiring doses higher than the observed mean dose to achieve the maximum effect, just as a proportion may well require lower doses. Regrettably the authors were unable to quantify this variability in response, as AstraZeneca were unable to make the individual patient data available and the interpretation of the study findings is limited in this respect.
Key findings
There was consistency in the findings from the different methods of analysis; the majority of the clinical effect of inhaled budesonide is achieved at a dose of 250–500 µg·day–1, with higher doses providing little further benefit. As with the previous meta-analysis of fluticasone 1, similar dose-response relationships were observed for the different outcome measures, including lung function, symptoms and exacerbations.
The findings are also consistent with other dose-response studies of budesonide that did not include a placebo arm and as a result could not be included in this meta-analysis 21–28. For example, similar results were found in the studies by Chanez et al. 22 and Tukiainen et al. 23, which showed no difference between initial treatment with 400 or 1,600 µg·day–1 budesonide after 4 weeks, or with 200 or 800 µg·day–1 after 12 weeks, respectively. In the FACET study 25, there were clinically significant improvements in asthma control with budesonide taken over a 12-month period at 800 as compared to 200 µg·day–1. In contrast, in the 4-week study by Van der Molen et al. 28, initial treatment with 200 or 800 µg·day–1 budesonide did not result in statistically significant differences for any of the clinical outcome measures. In the only randomised, double-blind study that compared doses of budesonide >1,600 µg·day–1, there was no therapeutic difference between 8 weeks of treatment with 3,200 and 1,600 µg·day–1, confirming the lack of further benefit at very high doses 21.
Cases when higher doses may be warranted
The asthmatic subjects recruited in the studies that were included in the meta-analysis can be considered to have had predominantly mild to moderate asthma, on the basis of a mean FEV1 69% pred. As a result, although some subjects with severe asthma were included in the studies (lower range in FEV1 40% pred), the findings may not necessarily apply to more severe asthmatics. As has been noted previously, due to individual variability, a proportion of asthmatics may require doses greater than the peak of the dose response observed in this meta-analysis to achieve maximal clinical benefit, just as a proportion may require lower doses.
Furthermore, the current findings do not exclude the possibility that there may be certain circumstances when higher doses of budesonide may be useful. There is some evidence that budesonide at 3,200 µg·day–1 may be as effective as oral corticosteroid therapy in follow-up treatment after an acute asthma attack 29. However, a recent meta-analysis by the Cochrane Collaboration suggests that further research is needed to clarify this and that insufficient evidence exists at present for such an inhaled regimen to be implemented 30.
Another clinical situation is the use of high doses of budesonide in oral steroid-dependent asthmatics to enable a reduction in oral steroid dose. Most studies have shown that a significant reduction in oral steroid dose can be achieved with high doses of inhaled corticosteroid therapy, although whether 1,600 µg·day–1 of budesonide is superior to 800 µg·day–1 is inconclusive 31–33.
Contrasting dose-response relationship of systemic effects
In contrast to the dose-response with efficacy, adverse systemic effects exhibit a more linear relationship with no evidence of a plateau in response. The two main adverse effects of concern with long-term use of inhaled corticosteroids in adults are adrenal suppression and reduced bone mineral density, with bruising, cataracts and glaucoma also being associated with their use. Studies have shown that doses >1,000 µg·day–1 of budesonide can produce significant suppression of the hypothalamic-pituitary-adrenal axis 34–36. Indeed, 6 weeks of budesonide treatment at a dose of 3,200 µg·day–1 may lead to suppression of adrenal cortisol production of a magnitude similar to that observed with 10 mg of oral prednisone 36.
The cumulative doses of inhaled corticosteroids are particularly important when the adverse effects on bone density are considered in relation to the requirement for life-long therapy. This is illustrated by Wong et al. 37, who calculated that the use of 2,000 µg·day–1 of budesonide or equivalent for 7 yrs results in a reduction of bone mineral density in the lumbar spine of at least 1 sd. In post-menopausal females, an effect of this magnitude is associated with a two-fold increase in fracture risk. As a result, patients currently treated with high doses of inhaled corticosteroids may well enter later life with reduced bone mineral density, as well as a degree of adrenal insufficiency. It is, therefore, important to consider the therapeutic index of inhaled corticosteroids, incorporating both the dose-response relationship for efficacy and systemic effects.
Comparison with guidelines and clinical practice
It is of concern to contrast the present findings with the therapeutic dose range recommended in national and international guidelines and formularies. For example, the recent British Guideline on the Management of Asthma recommends the use of inhaled corticosteroid with dose increments on the basis of clinical need, with provision for the dose of budesonide to be increased up to 2,000 µg·day–1 to obtain adequate control if this is not achieved at lower doses 2. Likewise, the British National Formulary gives a dose range for budesonide of 200–2,000 µg·day–1 for adults 4. Reducing the dose to within the therapeutic dose range would not only result in major financial savings, but also improve the risk-to-benefit ratio.
Therapeutic implications
One of the major therapeutic implications of these findings is at what dose of budesonide should a long-acting ß-agonist (LABA) be added if the patient has inadequately controlled asthma. The FACET study found that a four-fold increase in the dose of budesonide from 200 to 800 µg·day–1 was more effective than adding formoterol to budesonide 200 µg·day–1 for reducing severe exacerbations, which was the primary outcome variable 25. In contrast, the addition of formoterol to low-dose budesonide resulted in a greater reduction in symptoms and improvement in lung function. In the OPTIMA study of subjects with mild asthma, the addition of formoterol to 200 µg·day–1 of budesonide resulted in significantly greater efficacy for all outcome measures, including severe exacerbations, than increasing the dose of budesonide from 200 to 400 µg·day–1 26.
These studies indicate that considerable benefit can be achieved with the addition of a LABA to budesonide within the 200–800 µg·day–1 dose range and suggests that such an approach is preferable to increasing the dose of budesonide to a range beyond the dose-response profile observed in the present study.
Conclusions
This study provides more evidence that inhaled corticosteroids exhibit a flat dose-response at higher doses with most of the therapeutic benefit being achieved with a dose of 400 µg·day–1 budesonide or equivalent. Prescribing within the established therapeutic dose range for inhaled corticosteroids has an optimal risk-to-benefit ratio, whereas doses beyond the peak of the dose-response curve need to be prescribed with caution, as patients will be exposed to the potential adverse systemic effects of inhaled steroids with minimal further gain in terms of efficacy.
|
Acknowledgements |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
|
References |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  S Joos, A Miksch, J Szecsenyi, B Wieseler, U Grouven, T Kaiser, and A Schneider Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Thorax, May 1, 2008; 63(5): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert The Right Tools at the Right Time Chest, July 1, 2006; 130(1_suppl): 29S - 40S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Williams Considerations in the long-term management of asthma in ambulatory patients Am. J. Health Syst. Pharm., May 15, 2006; 63(10_Supplement_3): S14 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E Tattersfield When should a long acting {beta} agonist be added to an inhaled corticosteroid? Thorax, September 1, 2005; 60(9): 710 - 710. [Full Text] [PDF]
|
|
|
|
|
|
R Ruffin Peak expiratory flow (PEF) monitoring Thorax, November 1, 2004; 59(11): 913 - 914. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ingelf, J. Ekelund, and L.-G. Carlsson Meta-analysis on dose-response relationship of inhaled steroids must be done in homogenous asthma populations Eur. Respir. J., September 1, 2004; 24(3): 513 - 513. [Full Text] [PDF]
|
|
|
|
|
|
M. Masoli, M. Weatherall, S. Holt, and R. Beasley From the authors: Eur. Respir. J., September 1, 2004; 24(3): 513 - 514. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
